ClinicalTrials.gg
RecruitingNCT06059313Updated Jun 29, 2026

Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders

An observational study in Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD) and Frontal Variant of Alzheimer Disease, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.

Planned enrollment
12th of 25
120 · median 100
Started
2023
with 6 others
Observational
25 of 104
11 open now
Primary completion
2026-12
later than 15 of 37 live
Registered
85th of 104
by date

Among the 104 studies in Bipolar Disorder with a site in France, this one is the 12th largest by planned enrollment of the 25 observational ones that give a count, is one of 7 that started in 2023, is one of 25 observational ones, reaches primary completion later than 15 of the 37 other live ones, and was the 85th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Bipolar Disorder with a site in France, or all of them as a file.
02

Study summary

Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility.

The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.

03

Conditions studied

  • Behavioral Variant of Frontotemporal Disorder (bvFTD)
  • Phenocopy Frontotemporal Dementia (phFTD)
  • Frontal Variant of Alzheimer Disease
  • Bipolar Disorder

Browse trials for

Keywords

  • bvFTD
  • fvAD
  • phFTD
  • bipolar disorder,personality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted among eligible patients with bvFTD, fvAD, phFTD, followed to Memory Resource and Research Centre at Nantes university Hospital CMRR or referred to the department for a neuropsychological assessment (bipolar disorder). It will prospectively enroll 120 participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with behavioral variant of frontotemporal disorder (bvFTD) according to Rascovsky criteria (2011) or patients with phénocopy frontotemporal dementia (phFTD) who fulfill criteria for possible bvFTD and have no imaging abnormalities or patients with frontal variant of Alzheimer disease according to Ossenkopele criteria (2022), or patient with bipolar disorder according to CIM 10 criteria
  • Score for ≥ 18
  • Patient with caregiver who has who has known him/her in the 10 years preceding the disease onset.
  • Patient and caregiver consents (no opposition)

Exclusion criteria

Exclusion Criteria :

  • Patient with no caregiver
  • Pregnant or breast feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Behavioral variant of frontotemporal disorder (bvFTD)

    A group of participants who fulfill Rascovsky criteria (2011) for behavioural variant Frontotemporal Dementia

    Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)

  • Phenocopy frontotemporal dementia (phFTD)

    A group of participants who fulfill who fulfill Rascovsky criteria (2011) for possible behavioural variant Frontotemporal Dementia and have no imaging abnormalities.

    Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)

  • Frontal variant of Alzheimer disease

    A group of participants who fulfill Ossenkopele criteria (2022)

    Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)

  • Bipolar disorder

    A group of participants who fulfill CIM 10 criteria

    Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)

Interventions

  • OtherSubmission of the NEO-PI-3 questionnaire

    The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

  • OtherSubmission of the Interpersonal Reactivity Index questionnaire (IRI)

    The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

06

What researchers measure

Primary outcomes

  1. Premorbid personality traits

    Premorbid personality traits will be assessed by the NEO- NEO Personality Inventory-3 (NEO-PI-3). The NEO PI-3 measures the five major domains of personality: Neuroticism, Extraversion, Openness to experience, Conscientiousness and Agreeableness. Each domain is defined by 6 facets. NEOPI-3 includes 240 items and responses are made on a 5-point Likert -type scale ranging from strongly Disagree to strongly agree. The NEOPI 3 will be completed by a caregiver who has known the patient in the 10 years preceding the disease onset.

    Time frame: Baseline

Secondary outcomes

  1. Interpersonal Reactivity Index (IRI)

    IRI is a 28-item questionnaire measuring 4 aspects of empathy : perspective-taking, fantasy, empathic concern, personal distress. Each answer is rated from 1 (does not describe me well) to 5 (describes me very well).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 95 non-industry observational studies under Bipolar Disorder, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's planned 36 months is below that.

Counting every sponsor, half of 105 studies reached it within 64 months; a quarter within 31 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Sep 28, 2023
StartActual
Dec 14, 2023
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059313
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Dec 14, 2023
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Claire BOUTOLEAU-BRETONNIERE, PH
Contact
claire.boutoleaubretonniere@chu-nantes.fr
33 2 40 16 54 22
Laetitia BARBIN
Contact
laetitia.barbin@chu-nantes.fr
33 2 40 16 59 42

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion